Raiffeisen Bank International AG (RCEL)
Market Closed
10 Jul, 15:30
XWBO 
€
230. 46
+1.07
+0.47%
€
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
- Eps
€ 229.39
Previous Close Day Range
230.46 230.46
Year Range
201.65 233.16
Want to track RCEL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 24 days
Summary
RCEL closed Thursday higher at €230.46, an increase of 0.47% from Wednesday's close, completing a monthly decrease of -0.53% or €1.23. Over the past 12 months, RCEL stock gained 8.34%.
RCEL is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2025, missed the consensus estimates by -0.51%. On average, the company has fell short of earnings expectations by -0.21%, based on the last three reports. The next scheduled earnings report is due on Aug 07, 2025.
Raiffeisen Bank International AG has completed 1 stock splits, with the recent split occurring on Jun 30, 2020.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
RCEL Chart
AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call.
Seekingalpha | 2 months ago
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know
The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks | 4 months ago
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
Seekingalpha | 4 months ago
Raiffeisen Bank International AG Dividends
RCEL is not paying dividends to its shareholders.
Raiffeisen Bank International AG Earnings
| 14 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
RCEL is not paying dividends to its shareholders.
| 14 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
Raiffeisen Bank International AG (RCEL) FAQ
What is the stock price today?
The current price is €230.46.
On which exchange is it traded?
Raiffeisen Bank International AG is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is RCEL.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, no market cap data is available.
When is the next earnings date?
The next earnings report will release on Aug 07, 2025.
Has Raiffeisen Bank International AG ever had a stock split?
Raiffeisen Bank International AG had 1 splits and the recent split was on Jun 30, 2020.
Raiffeisen Bank International AG Profile
| Medical - Devices Industry | Healthcare Sector | James M. Corbett CEO | XWBO Exchange | US05380C1027 ISIN |
| US Country | 260 Employees | - Last Dividend | - Last Split | - IPO Date |
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Contact Information
Address: 28159 Avenue Stanford
Phone: 661 367 9170
Website: https://www.avitamedical.com
2025 © Marketlog. All Rights Reserved.
